Please login to the form below

Not currently logged in
Email:
Password:

CRISPR

This page shows the latest CRISPR news and features for those working in and with pharma, biotech and healthcare.

Gilead signs $3bn-plus gene-editing deal with Sangamo

Gilead signs $3bn-plus gene-editing deal with Sangamo

Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured TALENS.

Latest news

  • Price matters Price matters

    And so, in this brave new world of CAR-T and CRISPR and I/O therapies - to name a few - we continue to rely on governments to ensure that these therapies

  • Making a list and checking it twice… Making a list and checking it twice…

    The year 2017 looks to be the first in which humans are treated with CRISPR technology and where, despite Juno's misstep in CAR-T, Kite Pharma and Novartis could take

  • Bayer forms JV with gene editing firm CRISPR Bayer forms JV with gene editing firm CRISPR

    CRISPR-Cas9 introduces a break in a specific place within DNA and triggers a self-repair mechanism. ... However, instead of restoring the original sequence, CRISPR serves as a new template that can be used to modify the sequence.

  • Vertex forges ties with gene editing firm CRISPR Therapeutics Vertex forges ties with gene editing firm CRISPR Therapeutics

    Vertex forges ties with gene editing firm CRISPR Therapeutics. Aims to find new treatments for genetic diseases such as cystic fibrosis. ... of CRISPR-based therapeutics, delivered either directly in vivo or ex vivo using modified cells.

  • Novartis signs stem cell research pact with Intellia Novartis signs stem cell research pact with Intellia

    The deal aims to accelerate the ex vivo ('out of the living') development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoietic stem cells (HSCs). ... Our collaboration with Novartis is an important building

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA.

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

  • Deal Watch May 2016 Deal Watch May 2016

    Bayer and ERS signed a patent licence agreement giving Bayer access to ERS' CRISPR-Cas9 genome-editing patents. ... Earlier this month another CRISPR-Cas9 company, Intellia Therapeutics, raised $108m in an IPO to progress its early-stage programmes.

  • Deal Watch April 2016 Deal Watch April 2016

    265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Former GSK CEO joins Synthego’s advisory board Former GSK CEO joins Synthego’s advisory board

    Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing ... Becker said: “ I am excited to join the

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    CRISPR Therapeutics appoints Dr Tony Coles. He takes up a seat on the Swiss biopharma's board of directors. ... Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Creative Animodel

    Creative Animodel. Creative Animodel is an experienced bioscience CRO, which would like to help you accelerate the process through preclinical services including transgenic animals, animal models of disease, CRISPR genome editing

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics